Literature DB >> 21460508

Impact of chlorhexidine bathing on hospital-acquired infections among general medical patients.

Steven Z Kassakian1, Leonard A Mermel, Julie A Jefferson, Stephen L Parenteau, Jason T Machan.   

Abstract

BACKGROUND: A paucity of data exists regarding the effectiveness of daily chlorhexidine gluconate (CHG) bathing in non-intensive care unit (ICU) settings.
OBJECTIVE: To evaluate the effectiveness of daily CHG bathing in a non-ICU setting to reduce methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enteroccocus (VRE) hospital-acquired infections (HAIs), compared with daily bathing with soap and water.
DESIGN: Quasi-experimental study design; the primary outcome was the composite incidence of MRSA and VRE HAIs. Clostridium difficile HAI incidence was measured as a nonequivalent dependent variable with which to assess potential confounders.
SETTING: Four general medicine units, with a total of 94 beds, at a 719-bed academic tertiary-care facility in Providence, Rhode Island. PATIENTS: A total of 7,102 and 7,699 adult patients were admitted to the medical service in the control and intervention groups, respectively. Patients admitted from January 1 through December 31, 2008, were bathed daily with soap and water (control group), and those admitted from February 1, 2009, through March 31, 2010, were bathed daily with CHG-impregnated cloths (intervention group).
RESULTS: Daily bathing with CHG was associated with a 64% reduced risk of developing the primary outcome, namely, the composite incidence of MRSA and VRE HAIs (hazard ratio, 0.36 [95% CI, 0.2-0.8]; P = .01). There was no change in the incidence of C. difficile HAIs (P = .6). Colonization with MRSA was associated with an increased risk of developing a MRSA HAI (hazard ratio, 8 [95% CI, 3-19]; P < .001).
CONCLUSION: Daily CHG bathing was associated with a reduced HAI risk, using a composite endpoint of MRSA and VRE HAIs, in a general medical inpatient population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460508     DOI: 10.1086/658334

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  16 in total

1.  Effects of daily bathing with chlorhexidine and acquired infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a meta-analysis.

Authors:  Wensen Chen; Songqin Li; Lianhong Li; Xin Wu; Weihong Zhang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Using a Systems Engineering Initiative for Patient Safety to Evaluate a Hospital-wide Daily Chlorhexidine Bathing Intervention.

Authors:  Teresa Caya; Jackson Musuuza; Eric Yanke; Michelle Schmitz; Brooke Anderson; Pascale Carayon; Nasia Safdar
Journal:  J Nurs Care Qual       Date:  2015 Oct-Dec       Impact factor: 1.597

3.  The Two-Component System ChtRS Contributes to Chlorhexidine Tolerance in Enterococcus faecium.

Authors:  Ana M Guzmán Prieto; Jessica Wijngaarden; Johanna C Braat; Malbert R C Rogers; Eline Majoor; Ellen C Brouwer; Xinglin Zhang; Jumamurat R Bayjanov; Marc J M Bonten; Rob J L Willems; Willem van Schaik
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 4.  Resistant pathogens, fungi, and viruses.

Authors:  Christopher A Guidry; Sara A Mansfield; Robert G Sawyer; Charles H Cook
Journal:  Surg Clin North Am       Date:  2014-10-03       Impact factor: 2.741

5.  Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial.

Authors:  Susan S Huang; Edward Septimus; Ken Kleinman; Julia Moody; Jason Hickok; Lauren Heim; Adrijana Gombosev; Taliser R Avery; Katherine Haffenreffer; Lauren Shimelman; Mary K Hayden; Robert A Weinstein; Caren Spencer-Smith; Rebecca E Kaganov; Michael V Murphy; Tyler Forehand; Julie Lankiewicz; Micaela H Coady; Lena Portillo; Jalpa Sarup-Patel; John A Jernigan; Jonathan B Perlin; Richard Platt
Journal:  Lancet       Date:  2019-03-05       Impact factor: 79.321

6.  Chlorhexidine bathing and health care-associated infections: a randomized clinical trial.

Authors:  Michael J Noto; Henry J Domenico; Daniel W Byrne; Tom Talbot; Todd W Rice; Gordon R Bernard; Arthur P Wheeler
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

Review 7.  Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention.

Authors:  Irene K Louh; William G Greendyke; Emilia A Hermann; Karina W Davidson; Louise Falzon; David K Vawdrey; Jonathan A Shaffer; David P Calfee; E Yoko Furuya; Henry H Ting
Journal:  Infect Control Hosp Epidemiol       Date:  2017-04       Impact factor: 3.254

8.  Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.

Authors:  Vinay K Giri; Kristin G Kegerreis; Yi Ren; Lauren M Bohannon; Erica Lobaugh-Jin; Julia A Messina; Anita Matthews; Yvonne M Mowery; Elizabeth Sito; Martha Lassiter; Jennifer L Saullo; Sin-Ho Jung; Li Ma; Morris Greenberg; Tessa M Andermann; Marcel R M van den Brink; Jonathan U Peled; Antonio L C Gomes; Taewoong Choi; Cristina J Gasparetto; Mitchell E Horwitz; Gwynn D Long; Richard D Lopez; David A Rizzieri; Stefanie Sarantopoulos; Nelson J Chao; Deborah H Allen; Anthony D Sung
Journal:  Transplant Cell Ther       Date:  2021-01-07

Review 9.  Staphylococcus aureus - antimicrobial resistance and the immunocompromised child.

Authors:  J Chase McNeil
Journal:  Infect Drug Resist       Date:  2014-05-07       Impact factor: 4.003

10.  Minimal intervention for controlling nosocomial transmission of methicillin-resistant staphylococcus aureus in resource limited setting with high endemicity.

Authors:  Vincent Chi-Chung Cheng; Josepha Wai-Ming Tai; Pui-Hing Chau; Jonathan Hon-Kwan Chen; Mei-Kum Yan; Simon Yung-Chun So; Kelvin Kai-Wang To; Jasper Fuk-Woo Chan; Sally Cheuk-Ying Wong; Pak-Leung Ho; Kwok-Yung Yuen
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.